Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envoy MedicalCOCH +0.59%24 9-Day RSI is 44.74 as of Jul. 22, 2026. GuruFocus rates COCH with a GF Score™ of 24/100 and a GF Value™ of $1.12 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 866 Medical Devices & Instruments companies, Envoy Medical ranks better than 51.27% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-22), Envoy Medical's 9-Day RSI is 44.74.
The industry rank for Envoy Medical's 9-Day RSI or its related term are showing as below:
COCH's 9-Day RSI is ranked better than 51.27% of 866
companies
in the Medical Devices & Instruments industry
Industry Median: 45.18
vs COCH: 44.74
Envoy Medical (NAS:COCH) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Envoy Medical 9-Day RSI Related Terms
COCH vs SRTS, QTI, MDAI: 9-Day RSI Comparison
For the Medical Devices subindustry, Envoy Medical's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envoy Medical 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envoy Medical's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Envoy Medical's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envoy Medical (COCH) has a 9-Day RSI of 44.74 as of Jul. 22, 2026. According to the industry distribution chart, Envoy Medical ranks #422 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 48.7%.
Is Envoy Medical's 9-Day RSI too high?
Envoy Medical's current 9-Day RSI is 44.74. The Medical Devices & Instruments industry median 9-Day RSI is 45.18. Envoy Medical's value of 44.74 is 1% below this industry median. Based on the distribution chart, Envoy Medical ranks #422 out of 866 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Envoy Medical has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Envoy Medical's 9-Day RSI compare to SRTS and QTI?
According to the Medical Devices & Instruments industry distribution chart, Envoy Medical ranks #422 out of 866 companies for 9-Day RSI. This puts Envoy Medical in the upper half of its industry. The industry median 9-Day RSI is 45.18. Envoy Medical's value of 44.74 is 1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 45.18, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Envoy Medical's current 9-Day RSI of 44.74 is 1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 45.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envoy Medical's current 9-Day RSI is 44.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envoy Medical stock overvalued right now?
Based on GuruFocus' analysis, Envoy Medical (COCH) is currently considered Possible Value Trap. The stock's GF Value™ is $1.12, compared to a current price of $0.69 — trading 38.8% below its estimated fair value. The current 9-Day RSI is 44.74 and 1% below the Medical Devices & Instruments industry median of 45.18. Envoy Medical's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Envoy Medical (COCH), the current 9-Day RSI is 44.74 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envoy Medical (COCH) Overvalued in 2026?
Based on GuruFocus' analysis, Envoy Medical stock appears to be undervalued.
The current stock price of $0.69 is trading 38.8% below its estimated GF Value™ of $1.12.
GuruFocus considers Envoy Medical to be Possible Value Trap.
Key valuation signals for COCH:
9-Day RSI: 44.74
GF Value™: $1.12 vs. price of $0.69 (38.8% below fair value)
Industry Position: 1% below the Medical Devices & Instruments median (#422 of 866)
No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
24GF Score
Get the complete analysis for COCH
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COCH has been successfully added to your 
